20 years of experience with tumour necrosis factor inhibitors: what have we learned?

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologic disease-modifying antirheumatic drugs (DMARDs) targeting tumor necrosis factor (TNF) were approved for rheumatoid arthritis (RA) in the mid-1990s.
• TNF inhibitors remain a crucial therapy for controlling RA activity, disability, and radiographic progression.
• Diverse molecules and administration routes allow for personalized RA treatment strategies.

Purpose of the Study:

• To review the foundational principles of TNF inhibitor therapy in RA.
• To synthesize current knowledge on the therapeutic effects and adverse events associated with TNF inhibitors.
• To present updated data on safety concerns, including infections, malignancies, and cardiovascular risks.

Main Methods:

• Literature review focusing on TNF inhibitors for RA treatment.
• Analysis of data from drug registries regarding effectiveness.
• Compilation and assessment of safety data, including specific risks.

Main Results:

• TNF inhibitors offer significant control over RA disease activity, functional impairment, and joint damage.
• Personalized treatment approaches with various TNF inhibitors enhance patient management.
• Key safety considerations include risks for infections (e.g., tuberculosis, hepatitis B), cancers (lymphoma, skin), and cardiovascular events.

Conclusions:

• TNF inhibitors are integral to modern RA management, offering substantial benefits.
• Understanding their efficacy and safety profile is essential for optimal patient care.
• Ongoing monitoring for adverse events is critical for maximizing therapeutic outcomes in RA patients treated with TNF inhibitors.